Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03768531
Title Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

biliary tract cancer


Cabiralizumab + Nivolumab


Age Groups: senior | adult
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from for the field